• About BAYCELLator
  • Projects
      Project 1
        Project 2
          Project 3
            Project 4
              Project 5
                Project 6
                  Project 7
                    Project 8
                  • Publications
                  1. The Bavarian Cell Therapy Catalyst
                  2. Publications

                  Publications

                  Project 1-2.
                  Development of a chimeric antigen receptor that specifically and selectively recognizes acute myeloid leukemia (AML) blasts.Arming IPSC-derived NK cells with a CAR for treatment of AML

                  Stock S, Klüver AK, Fertig L, Menkhoff VD, Subklewe M, Endres S, Kobold S. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control. Int J Cancer. 2023 Jun 23. https://onlinelibrary.wiley.com/doi/10.1002/ijc.34635

                   

                  Märkl F , Schultheiß C , Murtaza A , Chen SS , Zintchenko M , Egli L , Mietz J , Chijioke O , Paschold L, Spajic S , Holtermann A , Dörr J , Stock S , Zingg A , Läubli H, Piseddu I , Anz D , Dühren-von Minden M , Zhang T , Nerreter T , Hudecek M , Minguet S , Chiorazzi N , Kobold S* , Binder M*: Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. * co-corresponding. Nature Communications 2024 Feb 2;15(1):993. https://www.nature.com/articles/s41467-024-45378-w

                  Project 4. Development of NK cells as an alternative cell source for adoptive cell therapy

                  Yazdi M, Hasanzadeh Kafshgari M, Khademi Moghadam F, Zarezade V, Oellinger R, Khosravi M, Haas S, Hoch CC, Pockley AG, Wagner E, Wollenberg B, Multhoff G, Bashiri Dezfouli A. Crosstalk between NK cell receptors and tumor membrane Hsp70-derived peptide: A combined computational and experimental study. Adv Sci: 2305998, doi: 10.1002/advs.202305998, 2024. https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202305998


                  Lennartz P, Thölke D, Bashiri Dezfouli A, Pilz M, Lobinger D, Messner V, Zanth H, Ainslie K, Kafshgari MH, Rammes G, Ballmann M, Schlegel M, Foulds GA, Pockley AG, Schmidt-Graf F, Multhoff G. Biomarkers in adult-type diffuse gliomas: Elevated levels of circulating vesicular heat shock protein 70 serve as a biomarker in grade 4 glioblastoma and increase nk cell frequencies in grade 3 glioma. Biomedicines 11(12): 3235, doi: 10.3390/biomedicines11123235, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10741018/


                  Xanthopoulos A, Samt AK, Guder C, Taylor N, Roberts E, Herf H, Messner V, Trill A, Holzmann KLK, Kiechle M, Seifert-Klauss V, Zschaeck S, Schatka I, Tauber R, Schmidt R, Enste K, Pockley AG, Lobinger D, Multhoff G. Hsp70-A universal biomarker for predicting therapeutic failure in human female cancers and a target for CTC isolation in advanced cancers. Biomedicines 11(8): 2276, doi: 10.3390/biomedicines 11082276, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452093/


                  Safi S, Messner L, Kliebisch M, Eggert L, Ceylangil C, Lennartz P, Jefferies B, Klein H, Schirren M, Dommasch M, Lobinger D, Multhoff G. Circulating Hsp70 Levels and the immunophenotype of peripheral blood lymphocytes as potential biomarkers for advanced lung cancer and therapy failure after surgery. Biomolecules 13: 874, doi: 10.3390/biom13050874, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216400/

                  Contact Details

                  Klinikum der Universität München. Abteilung Klinische Pharmakologie 

                  Lindwurmstrasse 2a
                  80337 München
                  +49 089 4400 57322 Klinische Pharmakologie, KUM

                  Supported by the Bavarian Research Foundation - Bayerische Forschungsstiftung

                  Contact Form

                  I agree to the data usage notice (see below). *

                  Security question (I'm not a robot!)

                  Data Usage Notice

                  Your personal data will be treated confidentially by us and will only be used to contact you by e-mail, telephone and/or in writing as part of this contact. Your information will be adequately protected against access by third parties and collected, processed and used in accordance with the provisions of the Federal Data Protection Act. The provision of your personal data, in particular your data on your health, is voluntary. If necessary, your request will be forwarded to the responsible departments or persons within the Munich University Hospital (KUM). In this context, there is the possibility that non-medical staff of the clinic may gain knowledge of the information you have disclosed. This information will not be passed on or transmitted to third parties outside the clinic. Your data will be deleted no later than 3 months after your information has been evaluated or forwarded to the responsible office. You can revoke your consent to the earmarked processing and use of the data at any time in writing without giving reasons. Your stored data will then be deleted immediately within the framework of legal regulations. The relevant information about your request will be sent or forwarded to you in unencrypted form at the email address you provided, without providing any information about your health. This poses a risk under data protection law. We will only send requested patient and personal application documents to a reasonable extent by post if you have given your postal address. Please also note our general data protection declaration

                  Login for editors
                  Imprint | Data-Safety

                  The Bavarian...

                  • About BAYCELLator
                  • Projects
                    • Project 1
                    • Project 2
                    • Project 3
                    • Project 4
                    • Project 5
                    • Project 6
                    • Project 7
                    • Project 8
                  • Publications